Eli Lilly & Co. (LLY) Declares $0.85 Quarterly Dividend; 1.5% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Eli Lilly resolves lobbyist's sex discrimination lawsuit
June 29, 2021 2:58 PM EDTBy Dan Levine and Marisa Taylor
(Reuters) - Eli Lilly & Co (NYSE: LLY) has resolved a lawsuit filed in March by a former top lobbyist who accused a high-ranking executive and another senior manager of engaging in sexual discrimination, harassment and retaliation against women in its Washington, D.C., office, according to a court filing on Monday.
The suit, filed in federal court in Washington by in-house lobbyist Sonya Elling alleged that a Lilly senior vice president, Leigh Ann Pusey, repeatedly demeaned Elling and other women, and eventually forced Elling to resign... More
U.S. Pauses Distribution of Eli Lilly & Co. (LLY) Antibody Combo on Resistance - Bloomberg
June 25, 2021 1:33 PM EDTU.S. Pauses Distribution of Eli Lilly & Co. (NYSE: LLY) Antibody Combo on Resistance - Bloomberg
Lilly's (LLY) SURPASS-2 results published in NEJM show tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes
June 25, 2021 11:39 AM EDTTirzepatide led to superior A1C and body weight reductions from baseline compared to injectable semaglutide 1 mg in 40-week results from Eli Lilly and Company's (NYSE: LLY) SURPASS-2 clinical trial, which were simultaneously published today in The New England Journal of Medicine (NEJM)1 and presented in a late breaking poster presentation during the American Diabetes Association's® (ADA) 81st Scientific Sessions®2. These... More
